University of Hertfordshire

Assessment of endogenous fibrinolysis in clinical using novel tests - Ready for clinical roll-out?

Research output: Contribution to journalArticlepeer-review

Standard

Assessment of endogenous fibrinolysis in clinical using novel tests - Ready for clinical roll-out? / Gue, Ying X.; Ding, Wern Yew; Lip, Gregory Y H; Gorog, Diana.

In: SN Applied Sciences, Vol. 3, No. 5, 524, 01.04.2021.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{fffab485d6b8461894754f54fc5e23c9,
title = "Assessment of endogenous fibrinolysis in clinical using novel tests - Ready for clinical roll-out?",
abstract = "The occurrence of thrombotic complications, which can result in excess mortality and morbidity, represent an imbalance between the pro-thrombotic and fibrinolytic equilibrium.The mainstay treatment of these complications involves the use of antithrombotic agents but despite advances in pharmacotherapy, there remains a significant proportion of patients who continue to remain at risk.Endogenous fibrinolysis is a physiological counter-measure against lasting thrombosis and may be measured using several techniques to identify higher risk patients who may benefit from more aggressive pharmacotherapy. However, the assessment of the fibrinolytic systemis not yet accepted into routine clinical practice.In this review, we will revisit the different methods of assessing endogenous fibrinolysis (factorial assays, turbidimetric lysis assays, viscoelastic and the global thrombosis tests), including the strengths, limitations, correlation to clinical outcomes of each method and howwe might integrate the assessment of endogenous fibrinolysis into clinical practice in the future.",
author = "Gue, {Ying X.} and Ding, {Wern Yew} and Lip, {Gregory Y H} and Diana Gorog",
note = "{\textcopyright} The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.",
year = "2021",
month = apr,
day = "1",
doi = "10.1007/s42452-021-04517-4",
language = "English",
volume = "3",
journal = "SN Applied Sciences",
issn = "2523-3971",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Assessment of endogenous fibrinolysis in clinical using novel tests - Ready for clinical roll-out?

AU - Gue, Ying X.

AU - Ding, Wern Yew

AU - Lip, Gregory Y H

AU - Gorog, Diana

N1 - © The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PY - 2021/4/1

Y1 - 2021/4/1

N2 - The occurrence of thrombotic complications, which can result in excess mortality and morbidity, represent an imbalance between the pro-thrombotic and fibrinolytic equilibrium.The mainstay treatment of these complications involves the use of antithrombotic agents but despite advances in pharmacotherapy, there remains a significant proportion of patients who continue to remain at risk.Endogenous fibrinolysis is a physiological counter-measure against lasting thrombosis and may be measured using several techniques to identify higher risk patients who may benefit from more aggressive pharmacotherapy. However, the assessment of the fibrinolytic systemis not yet accepted into routine clinical practice.In this review, we will revisit the different methods of assessing endogenous fibrinolysis (factorial assays, turbidimetric lysis assays, viscoelastic and the global thrombosis tests), including the strengths, limitations, correlation to clinical outcomes of each method and howwe might integrate the assessment of endogenous fibrinolysis into clinical practice in the future.

AB - The occurrence of thrombotic complications, which can result in excess mortality and morbidity, represent an imbalance between the pro-thrombotic and fibrinolytic equilibrium.The mainstay treatment of these complications involves the use of antithrombotic agents but despite advances in pharmacotherapy, there remains a significant proportion of patients who continue to remain at risk.Endogenous fibrinolysis is a physiological counter-measure against lasting thrombosis and may be measured using several techniques to identify higher risk patients who may benefit from more aggressive pharmacotherapy. However, the assessment of the fibrinolytic systemis not yet accepted into routine clinical practice.In this review, we will revisit the different methods of assessing endogenous fibrinolysis (factorial assays, turbidimetric lysis assays, viscoelastic and the global thrombosis tests), including the strengths, limitations, correlation to clinical outcomes of each method and howwe might integrate the assessment of endogenous fibrinolysis into clinical practice in the future.

U2 - 10.1007/s42452-021-04517-4

DO - 10.1007/s42452-021-04517-4

M3 - Article

VL - 3

JO - SN Applied Sciences

JF - SN Applied Sciences

SN - 2523-3971

IS - 5

M1 - 524

ER -